The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo

被引：0
|
作者：
Pemovska, Tea [1 ]
Kontro, Mika [2 ,3 ]
Repasky, Gretchen A. [1 ]
Porkka, Kimmo [2 ,3 ]
Wennerberg, Krister [1 ]
机构：
[1] FIMM, Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Hematol Res Unit Helsinki, Helsinki, Finland
[3] Univ Helsinki, Helsinki, Finland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4763
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4763
引用
收藏
页数：2
相关论文
共 50 条
  • [11] The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia
    Zafar, Usva
    Yusuf, Mohammed
    Chakraborty, Rikhia
    Lalani, El-Nasir M. A.
    Mian, Afsar Ali
    BLOOD, 2019, 134
  • [12] Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias
    Zou, Jing-Ying
    Huang, Si-Man
    Zhoub, Hai-Xia
    Xu, Ming-Zhu
    Sun, Ai-Ning
    Wu, De-Pei
    Xue, Sheng-Li
    Zhang, Tong-Tong
    HEMATOLOGY, 2023, 28 (01)
  • [13] PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
    A A Mian
    A Rafiei
    I Haberbosch
    A Zeifman
    I Titov
    V Stroylov
    A Metodieva
    O Stroganov
    F Novikov
    B Brill
    G Chilov
    D Hoelzer
    O G Ottmann
    M Ruthardt
    Leukemia, 2015, 29 : 1104 - 1114
  • [14] Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation
    Combes, Francois Pierre
    Sy, Sherwin K. B.
    Li, Ying Fei
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    CLINICAL PHARMACOKINETICS, 2024, 63 (09) : 1301 - 1312
  • [15] PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph plus ) leukemias harboring the T315I mutation
    Mian, A. A.
    Rafiei, A.
    Haberbosch, I.
    Zeifman, A.
    Titov, I.
    Stroylov, V.
    Metodieva, A.
    Stroganov, O.
    Novikov, F.
    Brill, B.
    Chilov, G.
    Hoelzer, D.
    Ottmann, O. G.
    Ruthardt, M.
    LEUKEMIA, 2015, 29 (05) : 1104 - 1114
  • [16] A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl
    Choi, Hwan Geun
    Ren, Pingda
    Adrian, Francisco
    Sun, Fangxian
    Lee, Hyun Soo
    Wang, Xia
    Ding, Qiang
    Zhang, Guobao
    Xie, Yongping
    Zhang, Jianming
    Liu, Yi
    Tuntland, Tove
    Warmuth, Markus
    Manley, Paul W.
    Mestan, Juergen
    Gray, Nathanael S.
    Sim, Taebo
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (15) : 5439 - 5448
  • [17] CLINICAL ROLE OF SECOND-GENERATION TYROSINE KINASE INHIBITOR FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE(PH+) LEUKEMIAS
    Usui, Noriko
    ANNALS OF ONCOLOGY, 2010, 21 : 9 - 10
  • [18] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Taira Maekawa
    Eishi Ashihara
    Shinya Kimura
    International Journal of Clinical Oncology, 2007, 12 : 327 - 340
  • [19] The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias
    Maekawa, Taira
    Ashihara, Eishi
    Kimura, Shinya
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2007, 12 (05) : 327 - 340
  • [20] PF-114, A NOVEL SELECTIVE PAN BCR/ ABL INHIBITOR FOR PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIA, EFFECTIVELY TARGETS T315I AND THE OTHER RESISTANCE MUTANTS
    Mian, A.
    Badura, S.
    Rafiei, A.
    Metodieva, A.
    Zeifman, A.
    Titov, I.
    Stroylov, V.
    Stroganov, O.
    Novikov, F.
    Ottmann, O.
    Chilov, G.
    Ruthardt, M.
    HAEMATOLOGICA, 2013, 98 : 488 - 489
12345